Radim Moravec, Ph.D., M.S.

Program Officer for Biomedical Informatics Projects

Clinical Trials Operations and Informatics Branch

NCI DCTD Cancer Therapy Evaluation Program

240-276-6072

Dr. Radim Moravec has scientific training in cancer biology, pharmacology and immunology from the University of Virginia. Prior to joining NIH, he was employed as an analytical chemist at GlaxoSmithKline, a virologist at Fox Chase Cancer Center, and a biomedical technology examiner for the US Patent and Trademark Office.

Dr. Moravec joined NCI in 2015 to work at the Surveillance Informatics Branch (DCCPS) where he helped to develop a Virtual Tissue Repository pilot aimed to enhance specimen and data collection capabilities of SEER cancer registries. From 2017 to 2022, Radim worked as a Scientific Program Manager in CDP and CBIIT on two Cancer Moonshot projects. He developed specimen and clinical data collection standards for over 30 clinical trials investigated by the Cancer Immune Monitoring and Analysis Centers (CIMAC) network, serving as a Lead Project Manager. He also served as a reviewer for CTEP PIO and for industry-funded study sections.

In CTOIB, Dr. Moravec provides oversight and planning of Medidata Rave Hosting and Maintenance, the Cancer Trials Support Unit (CTSU) core services; Enterprise systems; and awareness, education, and training activities. He also provides oversight and strategic planning for the Virtual Clinical Trials Office that assists clinical sites experiencing staffing shortages. Dr. Moravec has also taken a lead role in the oversight of the Centralized Coordination and Standardization of Electronic Health Record (EHR) Pilot aimed to establish a streamlined process for developing standardized EHR treatment plans for NCI-supported trials applicable across a broad range of clinical research sites.

Selected Publications

Sanchez P, et al. (2024) NCI SEER-Linked Virtual Tissue Repository Pilot. J Natl Cancer Inst Monogr. PMID: 39102878.

Parra ER, et al. (2024). Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial. Clin Cancer Res. PMID: 38277235.

Kaczanowska S, et al. (2024). Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer Cell. PMID: 38134936.

Chen HX, et al. (2021). Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clin Cancer Res. PMID: 33419780.